Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ulrich Storz
Observed names:
Storz, Ulrich,
U. Storz
Institution:
Michalski Huettermann and Partner
Observed institution:
Michalski Huettermann and Partner
ORCID:
0000-0002-9565-9857
Observed ORCID:
0000-0002-9565-9857
OpenAlex ID:
A5010293667
Intellectual property protection
2011
·
Ulrich Storz
·
mAbs
·
118
PDF
Rituximab
2014
·
Ulrich Storz
·
mAbs
·
43
PDF
Enhancing antibody patent protection using epitope mapping information
2017
·
Xiaoxiang Deng
, Ulrich Storz
, et al.
·
mAbs
·
33
PDF
Antibody-drug conjugates: Intellectual property considerations
2015
·
Ulrich Storz
·
mAbs
·
18
PDF
The COVID-19 vaccine patent race
2022
·
Ulrich Storz
·
Nature Biotechnology
·
16
PDF
Intellectual property issues of immune checkpoint inhibitors
2015
·
Ulrich Storz
·
mAbs
·
16
PDF
The patent maze of COVID 19 vaccines
2021
·
Ulrich Storz
·
Expert Opinion on Therapeutic Patents
·
14
Of patents and patent disputes: The TNFα patent files. Part 1: Humira
2016
·
Ulrich Storz
·
Human Antibodies
·
14
Antibody specification beyond the target: claiming a later-generation therapeutic antibody by its target epitope
2012
·
Colin G Sandercock
, Ulrich Storz
·
Nature Biotechnology
·
11
Extending the market exclusivity of therapeutic antibodies through dosage patents
2016
·
Ulrich Storz
·
mAbs
·
10
PDF
The CRISPR Cas patent files, part 1: Cas9 – Where to we stand at the 10 year halftime?
2023
·
Ulrich Storz
·
Journal of Biotechnology
·
9
CRISPR Cas9 − Licensing the unlicensable
2017
·
Ulrich Storz
·
Journal of Biotechnology
·
9
An update on obtaining and enforcing therapeutic antibody patent claims
2016
·
Theresa Gresl
, Ulrich Storz
, et al.
·
Nature Biotechnology
·
9
IP Issues of Therapeutic Antibodies
2012
·
Ulrich Storz
, Wolfgang Flasche
, et al.
·
SpringerBriefs in biotech patents
·
9
Biopatent Law: Patent Strategies and Patent Management
2012
·
Andreas Hübel
, Thilo Schmelcher
, et al.
·
SpringerBriefs in biotech patents
·
7
IP Issues in the Therapeutic Antibody Industry
2010
·
Ulrich Storz
·
Springer eBooks
·
7
International intellectual property strategies for therapeutic antibodies
2011
·
Ulrich Storz
·
mAbs
·
6
PDF
Intellectual Property Issues
2012
·
Ulrich Storz
, Wolfgang Flasche
, et al.
·
SpringerBriefs in biotech patents
·
5
Patent Lifecycle Management, Supplementary Protection Certificates and Data Exclusivity in Biopharmaceutics
2012
·
Ulrich Storz
·
SpringerBriefs in biotech patents
·
4
The CRISPR Cas patent files, part 2: Is Cpf1/Cas12a a less conflict- prone alternative to Cas9?
2024
·
Ulrich Storz
·
Journal of Biotechnology
·
3
Of patents and patent disputes – The TNFα patent files. Part 2: Enbrel, Remicade, Cimzia and Simponi
2018
·
Ulrich Storz
·
Human Antibodies
·
3
Biopatent Law: European vs. US Patent Law
2013
·
Ulrich Storz
, Martin Quodbach
, et al.
·
SpringerBriefs in biotech patents
·
3
Patentability Requirements of Biotech Patents
2013
·
Ulrich Storz
·
SpringerBriefs in biotech patents
·
3
The Cabilly patents
2012
·
Ulrich Storz
·
mAbs
·
3
PDF
Redefining antibody patent protection using paratope mapping and CDR-scanning
2025
·
Soma S. R. Banik
, Xiaoxiang Deng
, et al.
·
Nature Biotechnology
·
2
Show more works
View as search
Works count:
48
Citation count:
396
H-index:
10
I10-index:
10
Year
Topic
Type
